{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:36:12Z","timestamp":1787020572397,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Australian Research Council Center of Excellence in Convergent Bio-Nano Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Disruption of the cell cycle is among the most effective approach to increase tumour cells\u2019 radio-sensitivity. However, the presence of dose-limiting side effects hampers the clinical use of tyrosine kinase inhibitors targeting the cell cycle. Towards addressing this challenge, we identified a bosutinib nanoformulation within high density lipoprotein nanoparticles (HDL NPs) as a promising radiosensitiser. Bosutinib is a kinase inhibitor clinically approved for the treatment of chronic myeloid leukemia that possesses radiosensitising properties through cell cycle checkpoint inhibition. We found that a remarkably high bosutinib loading (&gt;\u200910%) within HDL NPs could be reliably achieved under optimal preparation conditions. The radiosensitisation activity of the bosutinib-HDL nanoformulation was first assessed in vitro in UM-SCC-1 head and neck squamous cell carcinoma (HNSCC) cells, which confirmed efficient disruption of the radiation induced G\n                    <jats:sub>2<\/jats:sub>\n                    \/M cell cycle arrest. Interestingly, the bosutinib nanoformulation out-performed free bosutinib, likely because of the specific affinity of HDL NPs with tumour cells. The combination of bosutinib-HDL NPs and radiotherapy significantly controlled tumour growth in an immunocompetent murine HNSCC model. The bosutinib-HDL nanoformulation also enhanced the radiation induced immune response through the polarisation of tumour associated macrophages towards proinflammatory phenotypes.\n                  <\/jats:p>","DOI":"10.1186\/s12951-023-01848-9","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T08:03:06Z","timestamp":1679385786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects"],"prefix":"10.1186","volume":"21","author":[{"given":"Pouya","family":"Dehghankelishadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Badiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle F.","family":"Maritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Dmochowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Thierry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"1848_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207528","author":"M Castedo","year":"2004","unstructured":"Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004. https:\/\/doi.org\/10.1038\/sj.onc.1207528.","journal-title":"Oncogene"},{"key":"1848_CR2","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-19-3373","volume":"26","author":"L Yang","year":"2020","unstructured":"Yang L, Shen C, Pettit CJ, Li T, Hu AJ, Miller ED, et al. Wee1 kinase inhibitor AZD1775 effectively sensitizes esophageal cancer to radiotherapy. Clin Cancer Res. 2020;26:3740\u201350.","journal-title":"Clin Cancer Res"},{"key":"1848_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.radonc.2016.11.017","volume":"122","author":"CJ Busch","year":"2017","unstructured":"Busch CJ, Kr\u00f6ger MS, Jensen J, Kriegs M, Gatzemeier F, Petersen C, et al. G2-checkpoint targeting and radiosensitization of HPV\/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1. Radiother Oncol. 2017;122:260\u20136.","journal-title":"Radiother Oncol"},{"key":"1848_CR4","doi-asserted-by":"publisher","first-page":"7863","DOI":"10.1021\/acs.jmedchem.7b00996","volume":"60","author":"JY Zhu","year":"2017","unstructured":"Zhu JY, Cuellar RA, Berndt N, Lee HE, Olesen SH, Martin MP, et al. Structural basis of wee kinases functionality and inactivation by diverse small molecule inhibitors. J Med Chem. 2017;60:7863\u201375.","journal-title":"J Med Chem"},{"key":"1848_CR5","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.4161\/cc.29214","volume":"13","author":"N Beeharry","year":"2014","unstructured":"Beeharry N, Banina E, Hittle J, Skobeleva N, Khazak V, Deacon S, et al. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints. Cell Cycle. 2014;13:2172\u201391.","journal-title":"Cell Cycle"},{"key":"1848_CR6","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2021.4905","author":"S Hu","year":"2021","unstructured":"Hu S, Xie D, Zhou P, Liu X, Yin X, Huang B, et al. LINCS gene expression signature analysis revealed bosutinib as a radiosensitizer of breast cancer cells by targeting eIF4G1. Int J Mol Med. 2021. https:\/\/doi.org\/10.3892\/ijmm.2021.4905.","journal-title":"Int J Mol Med"},{"key":"1848_CR7","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0555","author":"C Gambacorti-Passerini","year":"2019","unstructured":"Gambacorti-Passerini C, Le Coutre P, Piazza R. The role of bosutinib in the treatment of chronic myeloid leukemia. Futur Oncol. 2019. https:\/\/doi.org\/10.2217\/fon-2019-0555.","journal-title":"Futur Oncol"},{"key":"1848_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad2355","author":"S Ashton","year":"2016","unstructured":"Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, et al. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 2016. https:\/\/doi.org\/10.1126\/scitranslmed.aad2355.","journal-title":"Sci Transl Med"},{"key":"1848_CR9","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1200\/JCO.2019.37.15_suppl.3098","volume":"37","author":"ML Johnson","year":"2019","unstructured":"Johnson ML, Cosaert JGCE, Falchook GS, Jones SF, Strickland D, Greenlees C, et al. A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors. J Clin Oncol. 2019;37:3098\u20133098.","journal-title":"J Clin Oncol"},{"key":"1848_CR10","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1021\/acsnano.5b07522","volume":"10","author":"R Kuai","year":"2016","unstructured":"Kuai R, Li D, Chen YE, Moon JJ, Schwendeman A. High-density lipoproteins: nature\u2019s multifunctional nanoparticles. ACS Nano. 2016;10:3015\u201341.","journal-title":"ACS Nano"},{"key":"1848_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1593\/neo.101372","volume":"13","author":"MMK Shahzad","year":"2011","unstructured":"Shahzad MMK, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011;13:309\u201319.","journal-title":"Neoplasia"},{"key":"1848_CR12","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1021\/acsami.7b18525","volume":"10","author":"JS Rink","year":"2018","unstructured":"Rink JS, Sun W, Misener S, Wang JJ, Zhang ZJ, Kibbe MR, et al. Nitric oxide-delivering high-density lipoprotein-like nanoparticles as a biomimetic nanotherapy for vascular diseaseS. ACS Appl Mater Interfaces. 2018;10:6904\u201316.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1848_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00466","author":"LK Mooberry","year":"2016","unstructured":"Mooberry LK, Sabnis NA, Panchoo M, Nagarajan B, Lacko AG. Targeting the SR-B1 receptor as a gateway for cancer therapy and imaging. Front Pharmacol. 2016. https:\/\/doi.org\/10.3389\/fphar.2016.00466.","journal-title":"Front Pharmacol"},{"key":"1848_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2020.101064","author":"J Wang","year":"2021","unstructured":"Wang J, Zheng C, Zhai Y, Cai Y, Lee RJ, Xing J, et al. High-density lipoprotein modulates tumor-associated macrophage for chemoimmunotherapy of hepatocellular carcinoma. Nano Today. 2021. https:\/\/doi.org\/10.1016\/j.nantod.2020.101064.","journal-title":"Nano Today"},{"key":"1848_CR15","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1002\/adfm.201602600","volume":"26","author":"KM McMahon","year":"2016","unstructured":"McMahon KM, Plebanek MP, Thaxton CS. Properties of native high-density lipoproteins inspire synthesis of actively targeted in vivo siRNA delivery vehicles. Adv Funct Mater. 2016;26:7824\u201335.","journal-title":"Adv Funct Mater"},{"key":"1848_CR16","doi-asserted-by":"publisher","first-page":"11219","DOI":"10.18632\/oncotarget.14494","volume":"8","author":"KM McMahon","year":"2017","unstructured":"McMahon KM, Scielzo C, Angeloni NL, Deiss-Yehiely E, Scarfo L, Ranghetti P, et al. Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. Oncotarget. 2017;8:11219\u201327.","journal-title":"Oncotarget"},{"key":"1848_CR17","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1073\/pnas.1213657110","volume":"110","author":"S Yang","year":"2013","unstructured":"Yang S, Damiano MG, Zhang H, Tripathy S, Luthi AJ, Rink JS, et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci USA. 2013;110:2511\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1848_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aao1736","author":"R Kuai","year":"2018","unstructured":"Kuai R, Yuan W, Son S, Nam J, Xu Y, Fan Y, et al. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci Adv. 2018. https:\/\/doi.org\/10.1126\/sciadv.aao1736.","journal-title":"Sci Adv"},{"key":"1848_CR19","unstructured":"Final results of TARGET PHASE II study demonstrate the ability of CER-001, an HDL mimetic, to target tumor in patients with esophageal cancer. 2018 https:\/\/www.abionyx.com\/images\/pdfs\/images\/FINAL_results_pr_cerenis_pr__target_ENG_480cb.pdf Accessed 28 Oct 2021."},{"key":"1848_CR20","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1021\/acs.bioconjchem.9b00552","volume":"30","author":"D Pedersb\u00e6k","year":"2019","unstructured":"Pedersb\u00e6k D, Kr\u00e6mer MK, Kempen PJ, Ashley J, Braesch-Andersen S, Andresen TL, et al. The composition of reconstituted high-density lipoproteins (rHDL) dictates the degree of rHDL cargo\u2014and size-remodeling via direct interactions with endogenous lipoproteins. Bioconjug Chem. 2019;30:2634\u201346.","journal-title":"Bioconjug Chem"},{"key":"1848_CR21","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b06842","author":"P Kadiyala","year":"2019","unstructured":"Kadiyala P, Li D, Nunez FM, Altshuler D, Doherty R, Kuai R, et al. High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano. 2019. https:\/\/doi.org\/10.1021\/acsnano.8b06842.","journal-title":"ACS Nano"},{"key":"1848_CR22","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.2147\/IJN.S140591","volume":"12","author":"R Kuai","year":"2017","unstructured":"Kuai R, Subramanian C, White PT, Timmermann BN, Moon JJ, Cohen MS, et al. Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma. Int J Nanomedicine. 2017;12:6581\u201394.","journal-title":"Int J Nanomedicine"},{"key":"1848_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","volume":"16","author":"R Kuai","year":"2017","unstructured":"Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017;16:489\u201398.","journal-title":"Nat Mater"},{"key":"1848_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0360-3016(94)90269-0","volume":"29","author":"JA Bonner","year":"1994","unstructured":"Bonner JA, Maihle NJ, Folven BR, Christianson TJH, Spain K. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys. 1994;29:243\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1848_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2007.12.033","volume":"132","author":"A Sakaue-Sawano","year":"2008","unstructured":"Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell. 2008;132:487\u201398.","journal-title":"Cell"},{"key":"1848_CR26","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ijrobp.2016.01.028","volume":"95","author":"KC Cuneo","year":"2016","unstructured":"Cuneo KC, Morgan MA, Davis MA, Parcels LA, Parcels J, Karnak D, et al. Wee1 kinase inhibitor AZD1775 radiosensitizes hepatocellular carcinoma regardless of TP53 mutational status through induction of replication stress. Int J Radiat Oncol Biol Phys. 2016;95:782\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1848_CR27","first-page":"999","volume":"47","author":"BJ Fueger","year":"2006","unstructured":"Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006;47:999\u20131006.","journal-title":"J Nucl Med"},{"key":"1848_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/jpet.119.257568","volume":"372","author":"MV Fawaz","year":"2020","unstructured":"Fawaz MV, Kim SY, Li D, Ming R, Xia Z, Olsen K, et al. Phospholipid component defines pharmacokinetic and pharmacodynamic properties of synthetic high-density lipoproteins. J Pharmacol Exp Ther. 2020;372:193\u2013204.","journal-title":"J Pharmacol Exp Ther"},{"key":"1848_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jconrel.2021.07.026","volume":"337","author":"AH Najafabadi","year":"2021","unstructured":"Najafabadi AH, Abadi ZIN, Aikins ME, Foulds KE, Donaldson MM, Yuan W, et al. Vaccine nanodiscs plus polyICLC elicit robust CD8+ T cell responses in mice and non-human primates. J Control Release. 2021;337:168\u201378.","journal-title":"J Control Release"},{"key":"1848_CR30","doi-asserted-by":"publisher","first-page":"7783","DOI":"10.1021\/acs.nanolett.0c03414","volume":"20","author":"A Hassani Najafabadi","year":"2020","unstructured":"Hassani Najafabadi A, Zhang J, Aikins ME, Najaf Abadi ZI, Liao F, Qin Y, et al. Cancer immunotherapy via targeting cancer stem cells using vaccine nanodiscs. Nano Lett. 2020;20:7783\u201392.","journal-title":"Nano Lett"},{"key":"1848_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe7853","author":"MMT van Leent","year":"2021","unstructured":"van Leent MMT, Meerwaldt AE, Berchouchi A, Toner YC, Burnett ME, Klein ED, et al. A modular approach toward producing nanotherapeutics targeting the innate immune system. Sci Adv. 2021. https:\/\/doi.org\/10.1126\/sciadv.abe7853.","journal-title":"Sci Adv"},{"key":"1848_CR32","doi-asserted-by":"publisher","DOI":"10.1039\/C9NA00308H","author":"KD Ristroph","year":"2019","unstructured":"Ristroph KD, Prud\u2019homme RK. Hydrophobic ion pairing: Encapsulating small molecules, peptides, and proteins into nanocarriers. Nanoscale Adv. 2019. https:\/\/doi.org\/10.1039\/C9NA00308H.","journal-title":"Nanoscale Adv"},{"key":"1848_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejpb.2016.08.005","volume":"108","author":"P Prathipati","year":"2016","unstructured":"Prathipati P, Zhu J, Dong X. Development of novel HDL-mimicking \u03b1-tocopherol-coated nanoparticles to encapsulate nerve growth factor and evaluation of biodistribution. Eur J Pharm Biopharm. 2016;108:126\u201335.","journal-title":"Eur J Pharm Biopharm"},{"key":"1848_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121585","author":"P Dehghankelishadi","year":"2022","unstructured":"Dehghankelishadi P, Maritz MF, Badiee P, Thierry B. High density lipoprotein nanoparticle as delivery system for radio-sensitising miRNA: an investigation in 2D\/3D head and neck cancer models. Int J Pharm. 2022. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121585.","journal-title":"Int J Pharm"},{"key":"1848_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ctro.2021.01.013","volume":"27","author":"L Nissi","year":"2021","unstructured":"Nissi L, Suilamo S, Kyt\u00f6 E, Vaittinen S, Irjala H, Minn H. Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume. Clin Transl Radiat Oncol. 2021;27:139\u201346.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1848_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104750","author":"AR Jung","year":"2020","unstructured":"Jung AR, Roh JL, Kim JS, Choi SH, Nam SY, Kim SY. Post-treatment 18F-FDG PET\/CT for predicting survival and recurrence in patients with advanced-stage head and neck cancer undergoing curative surgery. Oral Oncol. 2020. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104750.","journal-title":"Oral Oncol"},{"key":"1848_CR37","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170442","author":"KJC Jacinto","year":"2017","unstructured":"Jacinto KJC, Co J, Mejia MB, Regala EE. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis. Br J Radiol. 2017. https:\/\/doi.org\/10.1259\/bjr.20170442.","journal-title":"Br J Radiol"},{"key":"1848_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24026","author":"P Strojan","year":"2016","unstructured":"Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M, Bossi P, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck. 2016. https:\/\/doi.org\/10.1002\/hed.24026.","journal-title":"Head Neck"},{"key":"1848_CR39","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","volume":"59","author":"TM Pawlik","year":"2004","unstructured":"Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:928\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1848_CR40","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1158\/0008-5472.CAN-16-0707","volume":"77","author":"M Sobecki","year":"2017","unstructured":"Sobecki M, Mrouj K, Colinge J, Gerbe F, Jay P, Krasinska L, et al. Cell-cycle regulation accounts for variability in Ki-67 expression levels. Cancer Res. 2017;77:2722\u201334.","journal-title":"Cancer Res"},{"key":"1848_CR41","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.celrep.2018.06.110","volume":"24","author":"I Miller","year":"2018","unstructured":"Miller I, Min M, Yang C, Tian C, Gookin S, Carter D, et al. Ki67 is a graded rather than a binary marker of proliferation versus quiescence. Cell Rep. 2018;24:1105-1112.e5.","journal-title":"Cell Rep"},{"key":"1848_CR42","first-page":"107","volume":"24","author":"T Takahashi","year":"2004","unstructured":"Takahashi T, Nakano T, Oka K, Ando K. Transitional increase in growth fraction estimated by Ki-67 index after irradiation to human tumor in xenograft. Anticancer Res. 2004;24:107\u201310.","journal-title":"Anticancer Res"},{"key":"1848_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19071824","author":"C Segrelles","year":"2018","unstructured":"Segrelles C, Contreras D, Navarro EM, Guti\u00e9rrez-Mu\u00f1oz C, Garc\u00eda-Escudero R, Paramio JM, et al. Bosutinib inhibits EGFR activation in head and neck cancer. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19071824.","journal-title":"Int J Mol Sci"},{"key":"1848_CR44","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1242\/jcs.108.6.2425","volume":"108","author":"V Baldin","year":"1995","unstructured":"Baldin V, Docommun B. Subcellular localisation of human wee1 kinase is regulated during the cell cycle. J Cell Sci. 1995;108:2425\u201332.","journal-title":"J Cell Sci"},{"key":"1848_CR45","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s11095-013-1046-z","volume":"31","author":"Q Lin","year":"2014","unstructured":"Lin Q, Chen J, Ng KK, Cao W, Zhang Z, Zheng G. Imaging the cytosolic drug delivery mechanism of HDL-like nanoparticles. Pharm Res. 2014;31:1438\u201349.","journal-title":"Pharm Res"},{"key":"1848_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2015.11.023","volume":"371","author":"JL Roh","year":"2016","unstructured":"Roh JL, Park JY, Kim EH, Jang HJ, Kwon M. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer. Cancer Lett. 2016;371:20\u20139.","journal-title":"Cancer Lett"},{"key":"1848_CR47","first-page":"431","volume":"5","author":"MM Jensen","year":"2015","unstructured":"Jensen MM, Kjaer A. Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies. Am J Nucl Med Mol Imaging. 2015;5:431\u201356.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"1848_CR48","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1535-7163.MCT-09-0962","volume":"9","author":"SA Rabbani","year":"2010","unstructured":"Rabbani SA, Valentino ML, Arakelian A, Ali S, Boschelli F. SKI-606 (bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther. 2010;9:1147\u201357.","journal-title":"Mol Cancer Ther"},{"key":"1848_CR49","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.18632\/oncotarget.13643","volume":"8","author":"S Bieerkehazhi","year":"2017","unstructured":"Bieerkehazhi S, Chen Z, Zhao Y, Yu Y, Zhang H, Vasudevan SA, et al. Novel Src\/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src\/Abl signaling. Oncotarget. 2017;8:1469\u201380.","journal-title":"Oncotarget"},{"key":"1848_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.211","author":"RR Weichselbaum","year":"2017","unstructured":"Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017. https:\/\/doi.org\/10.1038\/nrclinonc.2016.211.","journal-title":"Nat Rev Clin Oncol"},{"key":"1848_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0653-7","author":"C Lhuillier","year":"2019","unstructured":"Lhuillier C, Rudqvist NP, Elemento O, Formenti SC, Demaria S. Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med. 2019. https:\/\/doi.org\/10.1186\/s13073-019-0653-7.","journal-title":"Genome Med"},{"key":"1848_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-020-01390-w","author":"B Wang","year":"2020","unstructured":"Wang B, Sun L, Yuan Z, Tao Z. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation. Med Oncol. 2020. https:\/\/doi.org\/10.1007\/s12032-020-01390-w.","journal-title":"Med Oncol"},{"key":"1848_CR53","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4143\/crt.2019.183","volume":"52","author":"MH Jin","year":"2020","unstructured":"Jin MH, Nam AR, Park JE, Bang JH, Bang YJ, Oh DY. Therapeutic co-targeting of WEE1 and ATM downregulates PD-L1 expression in pancreatic cancer. Cancer Res Treat. 2020;52:149\u201366.","journal-title":"Cancer Res Treat"},{"key":"1848_CR54","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1442168","author":"KR Patel","year":"2018","unstructured":"Patel KR, Martinez A, Stahl JM, Logan SJ, Perricone AJ, Ferris MJ, et al. Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. Oncoimmunology. 2018. https:\/\/doi.org\/10.1080\/2162402X.2018.1442168.","journal-title":"Oncoimmunology"},{"key":"1848_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57456-2","author":"P Schr\u00f6ter","year":"2020","unstructured":"Schr\u00f6ter P, Hartmann L, Osen W, Baumann D, Offringa R, Eisel D, et al. Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-57456-2.","journal-title":"Sci Rep"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01848-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01848-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01848-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T08:06:27Z","timestamp":1679385987000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01848-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1848"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01848-9","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"26 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}